NCT04971512View on ClinicalTrials.gov

A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

PHASE1TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

December 20, 2021

Study Completion Date

December 20, 2021

Conditions
Chronic Hepatitis B Virus Infection
Interventions
DRUG

EDP-721

Oral administration (Part 1)

DRUG

Placebo (Part 1)

Placebo to match EDP-721, oral administration (Part 1)

DRUG

EDP-721 (Part 2)

Oral administration (Part 2)

DRUG

Placebo (Part 2)

Placebo to match EDP-721 (Part 2)

DRUG

EDP-514

Oral administration

DRUG

Placebo (Part 2)

Placebo to match EDP-514

Trial Locations (1)

1010

New Zealand Clinical Research Ltd, Auckland

Sponsors
All Listed Sponsors
lead

Enanta Pharmaceuticals, Inc

INDUSTRY

NCT04971512 - A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION. | Biotech Hunter | Biotech Hunter